Cost-effectiveness of a predictive biomarker for bevacizumab responsiveness in the primary treatment of ovarian cancer

被引：1
|
作者：
Barnett, I. [1 ]
Alvarez-Secord, A. [2 ]
Cohn, D. [3 ]
Leath, C. [1 ]
Peterson, B. [2 ]
Myers, E. [2 ]
Havrilesky, L. [2 ]
机构：
[1] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
[2] Duke Univ, Med Ctr, Durham, NC USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
GYNECOLOGIC ONCOLOGY | 2012年 / 125卷
关键词：
D O I：
10.1016/j.ygyno.2011.12.157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of bevacizumab for the treatment of advanced ovarian cancer in Canada
    Duong, M.
    Wright, E.
    Yin, L.
    Martin-Nunez, I.
    Ghatage, P.
    Fung-Kee-Fung, M.
    [J]. CURRENT ONCOLOGY, 2016, 23 (05) : E461 - E467
  • [2] Cost Effectiveness of Alternative Strategies for Incorporating Bevacizumab Into the Primary Treatment of Ovarian Cancer
    Barnett, Jason C.
    Secord, Angeles Alvarez
    Cohn, David E.
    Leath, Charles A., III
    Myers, Evan R.
    Havrilesky, Laura J.
    [J]. CANCER, 2013, 119 (20) : 3653 - 3661
  • [3] At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
    Cohn, David E.
    Kim, Kenneth H.
    Resnick, Kimberly E.
    O'Malley, David M.
    Straughn, J. Michael, Jr.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (10) : 1247 - 1251
  • [4] At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis
    Cohn, D.
    Kim, K.
    Resnick, K.
    O'Malley, D.
    Straughn, J.
    [J]. GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S12 - S13
  • [5] Bevacizumab in Treatment of High-Risk Ovarian Cancer-A Cost-Effectiveness Analysis
    Chan, John K.
    Herzog, Thomas J.
    Hu, Lilian
    Monk, Bradley J.
    Kiet, Tuyen
    Blansit, Kevin
    Kapp, Daniel S.
    Yu, Xinhua
    [J]. ONCOLOGIST, 2014, 19 (05): : 523 - 527
  • [6] BEVACIZUMAB FOR THE TREATMENT OF METASTATIC BREAST CANCER: A COST-EFFECTIVENESS ANALYSIS
    Fortune-Greeley, A.
    Cornell, P.
    [J]. VALUE IN HEALTH, 2010, 13 (03) : A34 - A34
  • [7] Utilizing a Pathomics Biomarker to Predict the Effectiveness of Bevacizumab in Ovarian Cancer Treatment
    Gilley, Patrik
    Zhang, Ke
    Abdoli, Neman
    Sadri, Youkabed
    Adhikari, Laura
    Fung, Kar-Ming
    Qiu, Yuchen
    [J]. BIOENGINEERING-BASEL, 2024, 11 (07):
  • [8] An economic analysis: Examining the cost-effectiveness of bevacizumab and olaparib as upfront maintenance treatment of advanced ovarian cancer
    Wolford, J. E.
    Liang, S. Y.
    Tewari, K. S.
    Eskander, R. N.
    Kapp, D. S.
    Mann, A. K.
    Chan, J. K.
    [J]. GYNECOLOGIC ONCOLOGY, 2019, 154 : 25 - 25
  • [9] Cost-effectiveness studies in ovarian cancer
    Szucs, TD
    Wyss, P
    Dedes, KJ
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 : 212 - 219
  • [10] Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer
    Mehta, Darshan A.
    Hay, Joel W.
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 677 - 683
12345